Inhibrx (INBX)

• Market cap: $1.35B
• 1 day: -0.9%
• 5 days: -6.11%
• 1 month: -1.43%
• 3 months: 18.99%
• 6 months: 25.78%
• Year to date: 22.83%
• 1 year: 301.44%
• 5 years: 636.77%
• 10 years: 636.77%
• Sector: Healthcare
• Industry: Biotechnology

About: Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.

Employees: 110